Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 3/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169089 | 0.86 | XDH (0.44) | MCHR1MAPTXDHRXFP1GRM1 | |
| SCHEMBL4165651 | 0.86 | MCHR1 (0.37) | MCHR1MAPTXDHRXFP1 | |
| SCHEMBL1689079 | 0.85 | MAPT (0.49) | MCHR1MAPTXDHRXFP1GRM1 | |
| SCHEMBL1689130 | 0.85 | MAPT (0.49) | MCHR1MAPTXDHRXFP1GRM1 | |
| SCHEMBL4704498 | 0.85 | MCHR1 (0.38) | MCHR1MAPTXDHMAPK13MAPK12 | |
| SCHEMBL4173644 | 0.85 | GRM1 (0.41) | MCHR1MAPTXDHGRM1 | |
| SCHEMBL15694340 | 0.84 | MAPT (0.41) | MCHR1MAPTXDHRXFP1GRM1 | |
| SCHEMBL4165904 | 0.84 | MCHR1 (0.41) | MCHR1MAPTXDHRXFP1GRM1 | |
| SCHEMBL4175211 | 0.84 | TDP2 (0.42) | MCHR1MAPTXDH | |
| SCHEMBL13651680 | 0.84 | GRM1 (0.40) | MCHR1MAPTXDHRXFP1GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| US-8722691-B2 | Azolopyrimidines as inhibitors of cannabinoid 1 activity | IRM LLC (BM) | 2014-05-13 | — | — | US | disclosed |
| EP-1999132-B1 | AZOLOPYRIMIDINES AS INHIBITORS OF CANNABINOID 1 ACTIVITY | IRM LLC (BM) | 2012-07-18 | — | — | EP | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247556-A1 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity | CNR1, CNR2, ITPR2 | MCHR1 1596/4885MAPT 2577/4885XDH 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.